1/11/2013

Inovio Pharmaceuticals could start clinical trials of SynCon HCV, its hepatitis C DNA vaccine, this year. Preclinical research found strong T-cell responses in the blood and liver. VGX International is paying for preclinical tests and human trials.

Related Summaries